Endoscopy Is Not Associated with Infectious Adverse Events After Hematopoietic Cell Transplantation : A Retrospective Cohort Study
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
BACKGROUND: Patients with recent hematopoietic cell transplantation (HCT) are considered high risk for gastrointestinal endoscopy due to the potential for procedural bacterial translocation. Prior studies investigating these risks do not account for the higher baseline rate of infectious complications among those who are immunocompromised. We performed a retrospective cohort study of patients with recent HCT who underwent endoscopy and their matched controls who did not undergo endoscopy.
METHODS: We identified patients who underwent HCT followed by upper and/or lower endoscopy at the University of Pennsylvania from 2000 to 2018. Individuals were matched 1:1 by age, sex, and type of HCT to controls who underwent HCT without subsequent endoscopy. Infectious adverse events were assessed by Sepsis-3 and Sepsis-2 criteria. Factors associated with infectious adverse events after endoscopy/index date were assessed using multivariable conditional logistic regression.
RESULTS: We identified 149 patients who underwent HCT and endoscopy and 149 matched controls who underwent HCT without endoscopy. Sepsis-3 infectious adverse events occurred in 3.4% of patients in each group. Sepsis-2 infectious adverse events occurred in 20.1% of patients who underwent endoscopy compared to 19.5% of controls. There was no association between endoscopy and Sepsis-2 infectious adverse events in the multivariable regression analysis (adjusted odds ratio 1.65, 95% CI 0.51-5.26).
CONCLUSIONS: When compared to controls with similar immune statuses, patients who underwent endoscopy after HCT did not have a higher risk of infectious adverse events. These results may inform clinical decision making regarding the risks and benefits of endoscopic management after HCT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Digestive diseases and sciences - 67(2022), 6 vom: 28. Juni, Seite 2310-2319 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Segura, Abraham [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Colonoscopy |
|---|
| Anmerkungen: |
Date Completed 08.06.2022 Date Revised 02.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10620-021-07062-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32599112X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32599112X | ||
| 003 | DE-627 | ||
| 005 | 20231225193625.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10620-021-07062-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1086.xml |
| 035 | |a (DE-627)NLM32599112X | ||
| 035 | |a (NLM)34050445 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Segura, Abraham |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endoscopy Is Not Associated with Infectious Adverse Events After Hematopoietic Cell Transplantation |b A Retrospective Cohort Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.06.2022 | ||
| 500 | |a Date Revised 02.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a BACKGROUND: Patients with recent hematopoietic cell transplantation (HCT) are considered high risk for gastrointestinal endoscopy due to the potential for procedural bacterial translocation. Prior studies investigating these risks do not account for the higher baseline rate of infectious complications among those who are immunocompromised. We performed a retrospective cohort study of patients with recent HCT who underwent endoscopy and their matched controls who did not undergo endoscopy | ||
| 520 | |a METHODS: We identified patients who underwent HCT followed by upper and/or lower endoscopy at the University of Pennsylvania from 2000 to 2018. Individuals were matched 1:1 by age, sex, and type of HCT to controls who underwent HCT without subsequent endoscopy. Infectious adverse events were assessed by Sepsis-3 and Sepsis-2 criteria. Factors associated with infectious adverse events after endoscopy/index date were assessed using multivariable conditional logistic regression | ||
| 520 | |a RESULTS: We identified 149 patients who underwent HCT and endoscopy and 149 matched controls who underwent HCT without endoscopy. Sepsis-3 infectious adverse events occurred in 3.4% of patients in each group. Sepsis-2 infectious adverse events occurred in 20.1% of patients who underwent endoscopy compared to 19.5% of controls. There was no association between endoscopy and Sepsis-2 infectious adverse events in the multivariable regression analysis (adjusted odds ratio 1.65, 95% CI 0.51-5.26) | ||
| 520 | |a CONCLUSIONS: When compared to controls with similar immune statuses, patients who underwent endoscopy after HCT did not have a higher risk of infectious adverse events. These results may inform clinical decision making regarding the risks and benefits of endoscopic management after HCT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Colonoscopy | |
| 650 | 4 | |a Endoscopy, digestive system | |
| 650 | 4 | |a Hematopoietic stem cell transplantation | |
| 650 | 4 | |a Immunosuppression | |
| 650 | 4 | |a Sepsis | |
| 700 | 1 | |a Dalal, Rahul S |e verfasserin |4 aut | |
| 700 | 1 | |a Golla, Meghana |e verfasserin |4 aut | |
| 700 | 1 | |a Gerson, James N |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmud, Nadim |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, James D |e verfasserin |4 aut | |
| 700 | 1 | |a Vajravelu, Ravy K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive diseases and sciences |d 1989 |g 67(2022), 6 vom: 28. Juni, Seite 2310-2319 |w (DE-627)NLM000356492 |x 1573-2568 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2022 |g number:6 |g day:28 |g month:06 |g pages:2310-2319 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10620-021-07062-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2022 |e 6 |b 28 |c 06 |h 2310-2319 | ||